Fifth Third Bancorp’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.03M | Hold |
4,600,000
| – | – | 0.01% | 696 |
|
|
2026
Q1 | $7.27M | Buy |
+4,600,000
| New | +$7.76M | 0.01% | 568 |
|
|
2022
Q4 | – | Sell |
-1,420
| Closed | -$2K | – | 2715 |
|
|
2022
Q3 | $2K | Hold |
1,420
| – | – | ﹤0.01% | 2441 |
|
|
2022
Q2 | $2K | Hold |
1,420
| – | – | ﹤0.01% | 2441 |
|
|
2022
Q1 | $2K | Hold |
1,420
| – | – | ﹤0.01% | 2534 |
|
|
2021
Q4 | $3K | Hold |
1,420
| – | – | ﹤0.01% | 2488 |
|
|
2021
Q3 | $4K | Hold |
1,420
| – | – | ﹤0.01% | 2270 |
|
|
2021
Q2 | $4K | Hold |
1,420
| – | – | ﹤0.01% | 2245 |
|
|
2021
Q1 | $3K | Hold |
1,420
| – | – | ﹤0.01% | 2269 |
|
|
2020
Q4 | $2K | Hold |
1,420
| – | – | ﹤0.01% | 2230 |
|
|
2020
Q3 | $1K | Hold |
1,420
| – | – | ﹤0.01% | 2174 |
|
|
2020
Q2 | $1K | Hold |
1,420
| – | – | ﹤0.01% | 2027 |
|
|
2020
Q1 | $1K | Hold |
1,420
| – | – | ﹤0.01% | 2045 |
|
|
2019
Q4 | $1K | Hold |
1,420
| – | – | ﹤0.01% | 2142 |
|
|
2019
Q3 | $1K | Hold |
1,420
| – | – | ﹤0.01% | 2114 |
|
|
2019
Q2 | $2K | Hold |
1,420
| – | – | ﹤0.01% | 2142 |
|
|
2019
Q1 | $2K | Buy |
+1,420
| New | +$1.77K | ﹤0.01% | 2053 |
|
|
2017
Q4 | – | Sell |
-4,801
| Closed | -$12K | – | 2318 |
|
|
2017
Q3 | $12K | Hold |
4,801
| – | – | ﹤0.01% | 1728 |
|
|
2017
Q2 | $13K | Hold |
4,801
| – | – | ﹤0.01% | 1666 |
|
|
2017
Q1 | $14K | Hold |
4,801
| – | – | ﹤0.01% | 1640 |
|
|
2016
Q4 | $15K | Hold |
4,801
| – | – | ﹤0.01% | 1687 |
|
|
2016
Q3 | $16K | Hold |
4,801
| – | – | ﹤0.01% | 1685 |
|
|
2016
Q2 | $11K | Hold |
4,801
| – | – | ﹤0.01% | 1776 |
|
|
2016
Q1 | $12K | Sell |
4,801
-403
| -8% | -$899 | ﹤0.01% | 1791 |
|
|
2015
Q4 | $17K | Hold |
5,204
| – | – | ﹤0.01% | 1746 |
|
|
2015
Q3 | $13K | Hold |
5,204
| – | – | ﹤0.01% | 1925 |
|
|
2015
Q2 | $15K | Hold |
5,204
| – | – | ﹤0.01% | 1919 |
|
|
2015
Q1 | $21K | Hold |
5,204
| – | – | ﹤0.01% | 1736 |
|
|
2014
Q4 | $16K | Hold |
5,204
| – | – | ﹤0.01% | 1792 |
|
|
2014
Q3 | $13K | Hold |
5,204
| – | – | ﹤0.01% | 1905 |
|
|
2014
Q2 | $13K | Hold |
5,204
| – | – | ﹤0.01% | 1927 |
|
|
2014
Q1 | $14K | Hold |
5,204
| – | – | ﹤0.01% | 1895 |
|
|
2013
Q4 | $15K | Hold |
5,204
| – | – | ﹤0.01% | 1749 |
|
|
2013
Q3 | $16K | Hold |
5,204
| – | – | ﹤0.01% | 1736 |
|
|
2013
Q2 | $17K | Buy |
+5,204
| New | +$16.7K | ﹤0.01% | 1644 |
|
Other funds holding LCTX
BC
DC
RA
Fifth Third Bancorp's LCTX Position: Q2 2026 in Review
Fifth Third Bancorp held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 4,600,000 shares worth $6.03M. The position accounts for 0.01% of the portfolio, ranked #696.
Fifth Third Bancorp first reported a position in LCTX in Q2 2013 and has held it in 35 quarters since. The position peaked at $7.27M in Q1 2026. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.
- Fifth Third Bancorp held 4,600,000 shares of Lineage Cell Therapeutics worth $6.03M as of Q2 2026.
- Fifth Third Bancorp left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
- Lineage Cell Therapeutics made up 0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #696 holding.
- Fifth Third Bancorp first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 35 quarters since.
- Fifth Third Bancorp's Lineage Cell Therapeutics position peaked at $7.27M in Q1 2026.
- 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.
Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.